Table 1 –
Patient, tumor, and surgical characteristics a
| Characteristic | RALP | RRP | p value |
|---|---|---|---|
| Patient characteristics | |||
| Patients, n (%) | 1847 (70) | 778 (30) | |
| Age at surgery (yr) | 63 (58–66) | 63 (59–67) | 0.035 |
| Smoking history | 0.2 | ||
| Never | 642 (35) | 300 (39) | |
| Former | 817 (44) | 332 (43) | |
| Current | 157 (8.5) | 57 (7.3) | |
| Unknown | 231 (13) | 88 (11) | |
| Body mass index (kg/m2) | 26 (24–28) | 26 (24–28) | 0.030 |
| <30 kg/m2 | 1424 (77) | 608 (78) | |
| ≥30 kg/m2 | 174 (9.4) | 74 (10) | |
| Unknown | 249 (13) | 95 (12) | |
| Partner at 24 mo | 1504 (81) | 635 (82) | 0.4 |
| Unknown | 172 (9.3) | 78 (10) | |
| History of cardiovascular disease | 570 (31) | 240 (31) | 0.9 |
| Unknown | 230 (12) | 91 (12) | |
| History of inguinal hernia | 266 (14) | 125 (16) | 0.3 |
| Unknown | 275 (15) | 110 (14) | |
| History of abdominal surgery | 362 (20) | 166 (21) | 0.3 |
| Unknown | 273 (15) | 109 (14) | |
| Diabetes | 102 (5.5) | 52 (6.7) | 0.3 |
| Unknown | 230 (12) | 88 (11) | |
| History of lung disease | 34 (1.8) | 19 (2.4) | 0.3 |
| Unknown | 232 (13) | 89 (11) | |
| History of mental disease | 57 (3.1) | 28 (3.6) | 0.5 |
| Unknown | 236 (13) | 88 (11) | |
| Continent at baseline | 1606 (87) | 674 (87) | 0.2 |
| Unknown | 224 (12) | 91 (12) | |
| Baseline erection sufficient for penetration | 1166 (63) | 488 (63) | 0.8 |
| Unknown | 260 (14) | 107 (14) | |
| Tumor and surgical characteristics | |||
| Degree of nerve sparing | <0.0001 | ||
| None | 531 (29) | 308 (40) | |
| Unilateral | 707 (38) | 167 (21) | |
| Bilateral | 603 (33) | 284 (37) | |
| Unknown | 6 (0.3) | 18 (2.3) | |
| Preoperative PSA (ng/ml) (n = 2597) | 6.1 (4.5–8.9) | 6.2 (4.5–9.0) | 0.8 |
| 0–4.4 ng/ml | 436 (24) | 189 (24) | |
| 4.5–6.1 ng/ml | 520 (28) | 196 (25) | |
| 6.2–9.1 ng/ml | 476 (26) | 200 (26) | |
| 9.2–20 ng/ml | 407 (22) | 173 (22) | |
| Unknown | 8 (0.4) | 19 (2.4) | |
| Pathology prostate weight (g) (n = 2577) | 42 (34–53) | 44 (36–55) | <0.0001 |
| 0–19 g | 18 (1.0) | 6 (0.8) | |
| 20–39 g | 792 (43) | 281 (36) | |
| 40–59 g | 719 (39) | 320 (41) | |
| 60–79 g | 209 (11) | 97 (12) | |
| ≥80 g | 86 (4.7) | 49 (6.3) | |
| Unknown | 23 (1.2) | 24 (3.1) | |
| Clinical T stage | 0.007 | ||
| T1 | 1099 (60) | 494 (64) | |
| T2 | 652 (35) | 218 (28) | |
| T3 | 57 (3.1) | 26 (3.3) | |
| Unknown | 39 (2.1) | 39 (5.0) | |
| Biopsy Gleason score | 0.7 | ||
| ≤7 | 1732 (94) | 716 (92) | |
| ≥8 | 102 (5.5) | 45 (5.8) | |
| Unknown | 13 (0.7) | 16 (2.1) | |
| Pathology T stage | 0.2 | ||
| T2 | 1287 (70) | 562 (72) | |
| T3 | 511 (28) | 190 (24) | |
| T4 | 10 (0.5) | 3 (0.4) | |
| Unknown | 39 (2.1) | 22 (2.8) | |
| Pathology Gleason score | 0.036 | ||
| ≤7 | 1674 (91) | 718 (92) | |
| ≥8 | 140 (7.6) | 41 (5.3) | |
| Unknown | 33 (1.8) | 18 (2.3) |
PSA = prostate-specific antigen.
a
Data are presented as median (interquartile range) for continuous variables and as n (%) for categorical variables.